Firm US sales keep Sun Pharma's outlook upbeat
The firm has been banking on its unfolded speciality portfolio in the US to support growth and thus offset some of the pricing pressure in the US generics base business10-10-2021
Firm US sales keep Sun Pharma's outlook upbeat
The firm has been banking on its unfolded speciality portfolio in the US to support growth and thus offset some of the pricing pressure in the US generics base businessSun Pharmaceutical Industries Q2 PAT seen up 15.6% YoY to Rs 2,094.8 cr: Prabhudas Lilladher
Net Sales are expected to increase by 13.3 percent Y-o-Y (down 0.9 percent Q-o-Q) to Rs 9,584.3 crore, according to Prabhudas Lilladher.Movers and Shakers: Stocks that will see action this week
Sun Pharmaceutical Ind (826.6)Breaks out afreshThe stock of Sun Pharmaceutical Industries, which has been on a steady rise since November last year aSun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 01, 2021 for Shanghvi Finance Pvt LtdSun Pharma gains 4% in 2 days after launching cough syrup Chericof 12
Chericof 12, the first prescription cough syrup in India which gives relief for up to 12 hours, is manufactured using Polistirex technology for sustained release of the drugSUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor MeetingSun Pharma launches Chericof 12 for cough management
It is manufactured using Polistirex technology for sustained release of the drugSUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015Sun Pharmaceutical Industries Ltd - 524715 - Closure of Trading Window
This is to inform you that in compliance with the Company''s Code of Conduct for prevention of Insider Trading, the window closure for trading by Designated Persons of the Company (along with his/her immediate relatives or any person with whom he/she shares a material financial relationship), shall be with effect from Friday, 1st October, 2021 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter ended 30th September, 2021. The date of the Board Meeting of the Company for declaration of the Unaudited Financial Results for the quarter ended 30th September, 2021 will be intimated in due course. This is for your information and record.